SpringerLink
Log in

Reply to: Caution at psychiatry’s psychedelic frontier and Challenges with benchmarking of MDMA-assisted psychotherapy

  • Matters Arising
  • Published:

From Nature Medicine

View current issue Submit your manuscript

The Original Article was published on 11 October 2021

The Original Article was published on 11 October 2021

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. https://doi.org/10.1038/s41591-021-01336-3 (2021).

  2. Halvorsen, J. Ø. et. al. Nat. Med. doi (2021).

  3. Burke, M. J. et. al. Nat. Med. doi (2021).

  4. Feduccia, A. A. et al. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front. Psychiatry September 2019, 1–7 (2019).

    Google Scholar 

  5. Jerome, L. et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacol. 237, 2485–2497 (2020).

    Article  CAS  Google Scholar 

  6. American Psychological Association. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults 1st edn (APA, 2017).

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of California, San Francisco, San Francisco, CA, USA

    Jennifer Mitchell & Allison Coker

  2. Department of Psychiatry & Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA

    Jennifer Mitchell

  3. San Francisco VA Medical Center, San Francisco, CA, USA

    Jennifer Mitchell

  4. MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA

    Allison Coker

  5. Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, USA

    Berra Yazar-Klosinski

Authors
  1. Jennifer Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Allison Coker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Berra Yazar-Klosinski
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J. M., A. C. and B. Y.-K. contributed to the writing of this manuscript.

Corresponding author

Correspondence to Jennifer Mitchell.

Ethics declarations

Competing interests

A. C. and B. Y.-K. received salary support for full-time employment with MAPS PBC/MAPS, the trial organizer and sponsor.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mitchell, J., Coker, A. & Yazar-Klosinski, B. Reply to: Caution at psychiatry’s psychedelic frontier and Challenges with benchmarking of MDMA-assisted psychotherapy. Nat Med 27, 1691–1692 (2021). https://doi.org/10.1038/s41591-021-01526-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01526-z

  • Springer Nature America, Inc.

Search

Navigation